
This study quantified the relative risk of ischemic stroke or systemic embolism and major bleeding (primary outcomes) and all-cause and cardiovascular death (secondary outcomes) among older individuals with cancer and nonvalvular atrial fibrillation comparing direct-acting oral anticoagulants (DOAC) and warfarin. Among 7675 individuals in the cohort, 4244 (55.3%) received DOACs and 3431 (44.7%) warfarin. Older adults with cancer and atrial fibrillation exposed to DOACs had similar risks of stroke, systemic embolism, and major bleeding as those exposed to warfarin. However, relative to warfarin, DOAC use was associated with a similar risk of cardiovascular death and a lower risk of all-cause death.
Like
Save
Share